Understanding Pharma Manufacturing’s Domestic Investment Surge: Part Two
In this episode of Off Script, we continue our conversation with David Grote, vice president of strategy at GrayMatter Partners, focusing on the execution challenges that will define the success of to...
20 Tammi 10min
Understanding Pharma Manufacturing’s Domestic Investment Surge: Part One
After years of volatility, pharmaceutical manufacturing is entering a new investment cycle, with hundreds of billions of dollars flowing into U.S. facilities. The surge promises expanded capacity, but...
13 Tammi 16min
AI and the Future of Drug Development
Artificial intelligence is rapidly reshaping drug development by accelerating timelines, enabling more complex biologics, and changing how therapies are designed, delivered, and scaled. But as innovat...
6 Tammi 23min
Predictive Maintenance for a Modern Cold Chain
While pharma supply chains are becoming increasingly digitized, the cold chain segment continues to face major vulnerabilities, from aging infrastructure and equipment failures to new refrigerant regu...
30 Joulu 202515min
Building a Future for Curative Cell Therapies: Part Two
In this episode of Off Script, we continue our conversation with Jason Bock, co-founder and CEO of CTMC, diving deeper into the operational and manufacturing challenges shaping the future of curative ...
23 Joulu 202513min
Building a Future for Curative Cell Therapies: Part One
Autologous cell therapies have shown the promise of single-dose, curative treatments for patients with advanced cancers. But even with major scientific and regulatory progress, the field now faces its...
16 Joulu 202517min
Modular Flow Chemistry and the Future of Continuous Manufacturing
Flow chemistry and modular continuous platforms are gaining momentum as pharma searches for faster, more flexible, and more sustainable ways to develop and scale small-molecule processes. Yet question...
9 Joulu 202516min
The Economics Behind U.S. Generic Drug Manufacturing: Part Two
In this episode of Off Script, we continue our conversation with John Murphy III, president and CEO of the Association for Accessible Medicines, to dig deeper into the vulnerabilities and structural c...
25 Marras 202516min
